{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ILMN",
  "name": "Illumina, Inc.",
  "url": "https://orbyd.app/dossiers/ILMN/",
  "json_url": "https://orbyd.app/dossiers/ILMN.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Beat-and-raise on 2026-07-30 (rev $1.159B +9.4%, EPS $1.31, FY26 guide up to $4.60–4.64B / $5.30–5.40) drew nine target hikes to as high as $230 — and the stock still closed 2026-08-07 at $187.96, 8.4% below the $205.10 high made on the print. Clinical/NovaSeq X conversion is intact; the flow has moderated and nothing company-dated is scheduled before the ~late-October Q3 print.",
  "invalidation_trigger": "A weekly close below $172 forfeits the July breakout above the 2026-06-25 high of $177.66 and unwinds the post-print range. Secondary: Q3 revenue under the $1.14B guide floor set 2026-07-30, or clinical consumables ex-China decelerating below mid-teens YoY.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "oncology-immunology",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "~44% academic/government mix; NIH/appropriations headlines are the standing macro risk.",
    "Headline clinical consumables growth is quoted EX-CHINA (+15% YoY in Q2 FY26). China sits outside that rate and is not carried in the number.",
    "Keith Meister (Corvex) sits on the board, so Corvex Form 4s are public and are the cleanest ongoing read on activist distribution;",
    "Management guides six to nine months from a clinical NovaSeq X placement to normalized consumables pull-through, so instrument counts lead revenue by two to three quarters.",
    "Analyst dispersion is unusually wide: Citigroup Sell $113 and Barclays Underweight $160 against RBC and JPMorgan at $230, all revised between 2026-07-31 and 2026-08-03."
  ],
  "body_markdown": "## Current Thesis\nThe clinical-sequencing inflection that this name was re-rated on stopped being a forecast on 2026-07-30. Q2 revenue came in at $1.159B (+9.4% YoY) against a $1.130B consensus, adjusted EPS $1.31 versus $1.23, and management raised FY26 to $4.600–4.640B revenue and $5.30–$5.40 adjusted EPS from $4.520–4.620B / $5.15–$5.30. Nine sell-side shops moved targets in the four sessions that followed, topping out at RBC and JPMorgan at $230 (both 2026-07-31). What the tape did with all of that is the interesting part: the 52-week high of $205.10 was printed into the release — $205.09 the session before, $202.95 after — and the close on 2026-08-07 was $187.96, 8.4% below the high, with RSI(14) at 52.5. The narrative leg an investor is buying here is the NovaSeq X installed-base conversion turning into recurring clinical consumables revenue over the next three to four quarters. The leg has moved from ACCELERATING to **MATURING**: it still works fundamentally, coverage is now near-universal, and the marginal bid has thinned. Nothing company-dated is scheduled between now and the Q3 print in late October.\n\n## Bull Case\n- Q2 FY26 (2026-07-30): revenue $1.159B, +9.4% YoY, beat the $1.130B consensus by ~2.5%; adjusted EPS $1.31 versus $1.23 estimated. Organic revenue growth 6.5% YoY — a step up from the +4.8% blended print in Q1 FY26 (2026-04-30).\n- Guidance raised on both lines the same day: FY26 revenue to $4.600–4.640B (prior $4.520–4.620B), adjusted EPS to $5.30–$5.40 (prior $5.15–$5.30). Q3 FY26 revenue outlook set at $1.14–1.16B.\n- Clinical consumables grew 15% YoY excluding China in Q2; clinical markets are now roughly 65% of sequencing consumables revenue, with US/Canada clinical growth above 20%.\n- Platform conversion is measurable, not aspirational: ~83% of sequencing volumes and ~59% of sequencing revenue had moved to NovaSeq X as of Q2 FY26, with more than 95 instruments placed in the quarter. Management targets 80–85% clinical volume conversion by end-2026.\n- Placement-to-consumables lag works in the forward direction: management flagged six to nine months for a clinical customer to reach normalized pull-through, so the Q2 instrument cohort is a 2027 consumables input already on the ground.\n- Adjusted operating income $260M in Q2 FY26, a 22.4% adjusted operating margin.\n- Every constructive target now sits above the 2026-08-07 close of $187.96: RBC $230 and JPMorgan $230 (07-31), Guggenheim $226 (07-31), Stifel $225 (07-31), Piper Sandler $225 (08-03), TD Cowen $210 (07-31), Canaccord $205 (08-03).\n- $1.5B repurchase authorization approved 2026-04-28.\n\n## Bear Case\n- The high was made on the news. Pre-print $205.09, post-print $202.95 (2026-07-30), and by 2026-08-07 the close was $187.96. A beat, a double guidance raise and nine target hikes produced eight days of give-back — the good news had been bought in advance.\n- Ratings did not follow the targets. Citigroup stayed Sell while lifting its target to $113 (2026-08-03); Barclays stayed Underweight at $160 (2026-07-31); Canaccord ($205) and TD Cowen ($210) remain Hold. Dispersion between $113 and $230 on the same quarter says the bear seat is still occupied.\n- Corvex/Keith Meister — the activist whose campaign drove the turnaround and who sits on the board — Every one of those prices is below where the stock trades now.\n- The headline clinical growth rate is quoted ex-China. China sits outside the +15% figure and has not been re-included at a comparable rate.\n- Q2 call commentary described research markets as improving sequentially but still cautious.\n- No scheduled company event until the Q3 print. An eleven-week gap with the story fully covered leaves the tape trading on fund flow and NIH appropriations headlines.\n- The multiple carries the load: the 2026-08-07 close of $187.96 is set against a raised FY26 adjusted EPS band of $5.30–$5.40 and 6.5% organic top-line growth.\n- Mainstream retail-facing coverage has arrived — a 2026-08-05 syndicated \"what $1,000 invested 20 years ago would be worth\" piece is the kind of look-back content that shows up after the move, not before it.\n\n## Setup & Price Structure\n- Last completed daily close $187.96 (2026-08-07). 52-week high $205.10, so the stock sits 8.4% below it. Three-month return +32.5%. RSI(14) 52.5.\n- Momentum has fully reset. RSI at 52.5 is neither extended nor washed out, which means the eight-day fade off $205.10 has neutralized the overbought condition without yet building a visible higher low.\n- The structure under price is the July advance itself. The 2026-06-25 high of $177.66 was the shelf the July leg cleared; that level, and the $172 area beneath it, is the first place where the July breakout stops being intact.\n- Overhead, $205.10 is a single-print high made on an earnings day. A weekly close back above it would say the consolidation resolved upward and the beat-and-raise finally got paid. Absent that, the name is in an unresolved range and the base has not re-formed.\n- Positioning observables, stated without a verdict: nine target revisions clustered inside 2026-07-31 to 2026-08-03; the highest constructive targets ($230) are ~22% above the 2026-08-07 close while the lowest ($113) is ~40% below; insider/activist open-market selling documented in May 2026 at $144–$165.50 with 3,500,048 shares still held indirectly after the last reported sale; no earnings date inside the next 30 days, so there is no near-term binary compressing implied volatility either way.\n\n## Catalyst Calendar (next 30 days)\n- **No confirmed company-dated event falls inside the window through ~2026-09-07.** The Q2 report (2026-07-30) has cleared and the next scheduled disclosure is a quarter away. That absence is itself the setup condition: price action through August is flow, not news.\n- **2026-09-30** — end of the US federal fiscal year / appropriations deadline. With roughly 44% of the mix academic and government, NIH funding and continuing-resolution headlines are the recurring macro input for this name and for the life-science tools complex generally.\n- **~2026-10-29 (est.)** — Q3 FY26 print. Q1 FY26 landed 2026-04-30 and Q2 FY26 landed 2026-07-30; the cadence points to late October, unconfirmed. This is the event that tests the $1.14–1.16B Q3 guide and whether the >95 NovaSeq X units placed in Q2 begin converting on the stated six-to-nine-month pull-through lag.\n- **Ongoing, undated** — Corvex Form 4 filings. There is no scheduled date, but each filing is the cleanest public read on whether the board-seated activist is still distributing above the May $147.50–$165.50 band.\n\n## What Would Change Our Mind\nThe structure that matters is the July leg that carried price above the 2026-06-25 high of $177.66 and up to $205.10. If that leg unwinds, the beat-and-raise stops being a base and becomes a lower high. A **weekly close below $172** forfeits the July breakout and the post-print range, and ends the momentum read on this narrative.\n\nThree non-price conditions would independently break the fundamental leg:\n1. Q3 FY26 revenue printing below the $1.14B floor of the guide issued 2026-07-30, or clinical consumables ex-China decelerating below mid-teens YoY after the +15% in Q2.\n2. Research & applied consumables deteriorating past the Q1 FY26 rate of -12% YoY, or an FY27 appropriations outcome that cuts NIH funding — the academic/government book is the pillar the bull case cannot carry alone.\n3. New Corvex open-market sales at prices above the May 2026 $147.50–$165.50 band, which would extend distribution into the re-rating rather than ahead of it.\n\nOn the other side, a weekly close above $205.10 with the range expanding would say the consolidation resolved up and the target cluster at $205–$230 is being priced rather than ignored. Absent either resolution, this is a name in an unresolved range with no scheduled catalyst, and chasing into that is a low-quality entry regardless of how good the quarter was.\n\n## Correlation Notes\n- Life-science tools complex: moves with QGEN, TMO, A, DHR, RVTY and PACB on shared NIH/academic funding and capital-equipment-cycle headlines. The ~44% academic-government mix makes ILMN one of the higher-beta expressions of federal research funding in the group.\n- Clinical testing customers — EXAS, NTRA, GH, WGS — are the demand side of the consumables story. Their volume commentary reads through directly to Illumina's clinical consumables line, which is now ~65% of sequencing consumables revenue.\n- China: Q2 clinical growth was reported ex-China, so Chinese procurement, stimulus and localization headlines move a component of results that the headline growth rate does not contain.\n- Rate/duration: a long-duration healthcare-growth multiple against a $5.30–$5.40 FY26 EPS band; the name tends to track XBI/IBB risk appetite on rate repricing days more than it tracks the S&P.\n- Competitive read-across: any high-throughput sequencing announcement from Roche, Element or Ultima is a direct input to the switching-cost assumption that JPMorgan's 2026-06-10 upgrade was built on, and Canaccord's June 2026 downgrade rationale rested on.",
  "first_seen": "2026-05-14",
  "last_analyzed": "2026-08-08T16:00:05+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}